BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24583195)

  • 1. A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination.
    Yin L; Stern LJ
    J Immunol Methods; 2014 Apr; 406():21-33. PubMed ID: 24583195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives.
    Yin L; Calvo-Calle JM; Dominguez-Amorocho O; Stern LJ
    J Immunol; 2012 Oct; 189(8):3983-94. PubMed ID: 22966084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization.
    Yin L; Stern LJ
    Curr Protoc Immunol; 2014 Aug; 106():5.10.1-5.10.12. PubMed ID: 25081912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DM catalytically enhances peptide dissociation by sensing peptide-MHC class II interactions throughout the peptide-binding cleft.
    Reyes-Vargas E; Barker AP; Zhou Z; He X; Jensen PE
    J Biol Chem; 2020 Mar; 295(10):2959-2973. PubMed ID: 31969393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide.
    Yin L; Trenh P; Guce A; Wieczorek M; Lange S; Sticht J; Jiang W; Bylsma M; Mellins ED; Freund C; Stern LJ
    J Biol Chem; 2014 Aug; 289(34):23449-64. PubMed ID: 25002586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct editing functions of natural HLA-DM allotypes impact antigen presentation and CD4
    Álvaro-Benito M; Morrison E; Ebner F; Abualrous ET; Urbicht M; Wieczorek M; Freund C
    Cell Mol Immunol; 2020 Feb; 17(2):133-142. PubMed ID: 30467419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of peptide repertoire selection by HLA-DM.
    Pos W; Sethi DK; Wucherpfennig KW
    Trends Immunol; 2013 Oct; 34(10):495-501. PubMed ID: 23835076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
    Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
    Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability.
    Lazarski CA; Chaves FA; Sant AJ
    J Exp Med; 2006 May; 203(5):1319-28. PubMed ID: 16682499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutting edge: TCR contacts as anchors: effects on affinity and HLA-DM stability.
    Anderson MW; Gorski J
    J Immunol; 2003 Dec; 171(11):5683-7. PubMed ID: 14634075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility.
    Álvaro-Benito M; Morrison E; Abualrous ET; Kuropka B; Freund C
    Front Immunol; 2018; 9():872. PubMed ID: 29774024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidomic analysis of type 1 diabetes associated HLA-DQ molecules and the impact of HLA-DM on peptide repertoire editing.
    Zhou Z; Reyes-Vargas E; Escobar H; Chang KY; Barker AP; Rockwood AL; Delgado JC; He X; Jensen PE
    Eur J Immunol; 2017 Feb; 47(2):314-326. PubMed ID: 27861808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-DM mediates epitope selection by a "compare-exchange" mechanism when a potential peptide pool is available.
    Ferrante A; Anderson MW; Klug CS; Gorski J
    PLoS One; 2008; 3(11):e3722. PubMed ID: 19005572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes.
    Belmares MP; Busch R; Wucherpfennig KW; McConnell HM; Mellins ED
    J Immunol; 2002 Nov; 169(9):5109-17. PubMed ID: 12391227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-DM and the MHC class II antigen presentation pathway.
    Jensen PE; Weber DA; Thayer WP; Chen X; Dao CT
    Immunol Res; 1999; 20(3):195-205. PubMed ID: 10741860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional HLA-DM on the surface of B cells and immature dendritic cells.
    Arndt SO; Vogt AB; Markovic-Plese S; Martin R; Moldenhauer G; Wölpl A; Sun Y; Schadendorf D; Hämmerling GJ; Kropshofer H
    EMBO J; 2000 Mar; 19(6):1241-51. PubMed ID: 10716924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.
    Busch R; Rinderknecht CH; Roh S; Lee AW; Harding JJ; Burster T; Hornell TM; Mellins ED
    Immunol Rev; 2005 Oct; 207():242-60. PubMed ID: 16181341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway.
    Schulze MS; Wucherpfennig KW
    Curr Opin Immunol; 2012 Feb; 24(1):105-11. PubMed ID: 22138314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules.
    Vogt AB; Kropshofer H; Hämmerling GJ
    Hum Immunol; 1997 May; 54(2):170-9. PubMed ID: 9297535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-presenting cells and the selection of immunodominant epitopes.
    Blum JS; Ma C; Kovats S
    Crit Rev Immunol; 1997; 17(5-6):411-7. PubMed ID: 9419428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.